Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-FR Version v8-FR
Language French French
Date Updated 2022-08-26 2022-07-12
Drug Identification Number 02472961 02472961
Brand name KEVZARA KEVZARA
Common or Proper name sarilumab 1.14 mL pre-filled pen sarilumab 1.14 mL pre-filled pen
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients SARILUMAB SARILUMAB
Strength(s) 150MG 150MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size 2 pen per carton 2 pen per carton
ATC code L04AC L04AC
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2022-04-18 2022-04-18
Estimated end date 2022-08-25 2022-08-05
Actual end date 2022-08-25
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Manufacturing delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Manufacturing delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date.
Health Canada comments